Subscribe To Our Free Newsletter |
Biocon Biologics set to introduce YESAFILI, a proposed biosimilar to EYLEA in Canadian market
Biocon Biologics, a subsidiary of Biocon, has announced the signing of a settlement with Bayer Inc. and Regeneron Pharmaceuticals, Inc. This Agreement paves the way for the introduction of YESAFILI, a proposed biosimilar to EYLEA (aflibercept) Injection, into the Canadian market.